Pneumococcal conjugate second or third-dose vaccines (PCVc) in Portugal
Portugal: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 98.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Portugal, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Portugal recorded 98.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
The figure is unchanged over five years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Portugal peaked at 98.0% in 2018 and was at its lowest, 0.0%, in 2008.
That places Portugal 11th out of 194 countries with data for 2025, putting it in the top 10%.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Portugal, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 73.0% | — |
| 2017 | 96.0% | +31.5% |
| 2018 | 98.0% | +2.1% |
| 2019 | 98.0% | +0.0% |
| 2020 | 98.0% | +0.0% |
| 2021 | 98.0% | +0.0% |
| 2022 | 98.0% | +0.0% |
| 2023 | 98.0% | +0.0% |
| 2024 | 98.0% | +0.0% |
| 2025 | 98.0% | +0.0% |
Portugal compared with similar countries
- Portugal's 98.0% is above the median for high income countries, which is 91.0%, 1.1× the median. (63 countries reporting)
- Portugal's 98.0% is above the median for Europe & Central Asia, which is 87.0%, 1.1× the median. (51 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 36.5% | 0.0% | 98.0% | 10 |
| 2020s | 98.0% | 98.0% | 98.0% | 6 |
Countries ranked near Portugal
- 11 Turkmenistan 98.0% compare
- 11 El Salvador 98.0% compare
- 11 Costa Rica 98.0% compare
- 11 Saudi Arabia 98.0% compare
- 11 Mauritius 98.0% compare
More health data for Portugal
- Un projection of annual infant deaths, annual growth rate -2.56 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.1616 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,112 deaths per 1,000 people (2090)
- Number of infants who die before age 1 38 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 1.39 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0199 units per person (2025)
- Population ages 00-04, male, annual growth rate 1.15 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Portugal?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Portugal was 98.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Portugal?
- The highest recorded value was 98.0% in 2018.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Portugal?
- The lowest recorded value was 0.0% in 2008.
- How does Portugal rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Portugal ranks 11th out of 194 countries with data for 2025.
- Where does this Portugal data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).